极目峰睿（上海）生物科技有限公司

我们致力于成为中国领先的眼科企业，专注于开发具有高商业价值的突破性眼科新药，布局例如基因治疗、罕见病等高科技领域，以解决眼科疾病中尚未满足的临床治疗需求，引领中国眼科治疗市场。

我们由一支由眼科行业资深人士组成的精英团队领导，在眼科产品的研发和商业化领域拥有丰富的中国和国际成功经验。

我们从产品引进模式开始，建立具有中国至亚洲权利、全面覆盖眼科疾病种类的产品管线，并通过持续性产品引进和内部新药研发平台，逐步扩展到具有全球权利的产品组合。

我们获得了顶级生命科技风险投资公司的支持，他们在中国和欧美眼科市场拥有丰富的资源及资深的经验，成功孵化了众多中国企业。



We aim to become a leading specialty ophthalmology company in China with a portfolio of breakthrough technologies to lead China vision market with international exposure.

We are led by an elite team of ophthalmic industry veterans with substantial and successful China and global experiences in R&D and commercialization of eye care products.

We start with a license-in model to build a 3-5 assets pipeline with Greater China rights, and will gradually expand to a portfolio with global rights via diverse approaches including license-in deals and internal discovery & development platform.

We are backed by top-tier biotech venture capitals with broad network in both China and US/EU ophthalmic markets, in-depth knowledge and unprecedented track record in company incubation in China.